Show simple item record

dc.contributor.authorSemchenko, Evgeny A
dc.contributor.authorSeib, Kate L
dc.date.accessioned2019-04-03T23:17:59Z
dc.date.available2019-04-03T23:17:59Z
dc.date.issued2016
dc.identifier.issn1368-4973
dc.identifier.doi10.1136/sextrans-2015-052378
dc.identifier.urihttp://hdl.handle.net/10072/100184
dc.description.abstractNeisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhoea, is an ancient disease with biblical references.1 Despite ongoing efforts towards treatment and prevention, gonorrhoea remains a major public health problem worldwide with an estimated global incidence of 106 million cases/year,2 leading to direct and indirect costs that exceed $1 billion/year in the USA alone.3 The clinical outcomes of gonococcal infection range from asymptomatic infection to severe sequelae (reviewed in refs. 4, 5). Symptomatic infection typically presents as urethritis in males and cervicitis in females; however, mucosal infections of the rectum, pharynx and eye are also reported. In addition, asymptomatic infections occur in 50–80% of infected females and 1%–40% of infected males, which, if left undiagnosed or untreated, can lead to sequelae that include urogenital tract abscesses, pelvic inflammatory disease, adverse pregnancy outcomes, infertility and neonatal complications. Infection with N. gonorrhoeae also increases the risk of acquiring and transmitting HIV.
dc.languageEnglish
dc.publisherBMJ Group
dc.relation.ispartofpagefrom1
dc.relation.ispartofpageto2
dc.relation.ispartofjournalSexually Transmitted Infections
dc.subject.fieldofresearchPublic Health and Health Services not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchMedical Microbiology
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode111799
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1108
dc.subject.fieldofresearchcode1117
dc.subject.keywordsGonorrhoea
dc.subject.keywordsVaccine
dc.subject.keywordsAsymptomatic infection
dc.subject.keywordsSevere sequelae
dc.titleIntractable problems require novel solutions: it’s time to get serious about developing a gonorrhoea vaccine
dc.typeJournal article
dc.type.descriptionC2 - Articles (Other)
dc.type.codeC - Journal Articles
gro.facultyGriffith Sciences, School of Natural Sciences
gro.rights.copyright© The Author(s) 2016. This is the author-manuscript version of this paper. It is posted here with permission of the copyright owner(s) for your personal use only. No further distribution permitted. For information about this journal please refer to the publisher’s website or contact the author(s).
gro.hasfulltextFull Text
gro.griffith.authorSemchenko, Evgeny
gro.griffith.authorSeib, Kate


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record